☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Dementia
BioXcel's BXCL501 Receives the US FDA's Breakthrough Therapy Designation for Acute Treatment of Agitation Associated with Dementia
March 15, 2021
Eisai and Cogstate Expand their Agreement to Develop and Commercialize Digital Cognitive Assessment Technologies
October 26, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.
